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1.  INDRODUCTION 
 
The siddha system date backs to 5000 B.C Profounded by saint Agathiyar and his 
clan numbering 18 such siddhars. This system is an amalgam of Tamil literature, culture, 
tradition, Health and many such living forms of 64 types. 
The National Institute of Siddha was started on 30.9.2004 and the department of 
Gunapadam is also functioning on this date. So Many researches have been carried out 
for animal experimentation and drug profile. 
The Present Study About The Safety and Pharmacological Profile Of Thirikadugu 
Dravagam On Animal Models. 
The experiment was permitted by IAEC approval constituted by KK College of 
pharmacy, Gerugambakkam, and the study is met with the relevant OECD Guidelines & 
CPCSEA norms also. 
The standard operative procedure was followed and the drug labeling was done. 
          Review of the Ingridients, Chemical analysis, Phytochemical analysis, shows 
sufficient Molecules of therapeutic benefits for the safety and efficacy of the drug 
Thirikadugu Dravagam. 
Analytical study includes, Organoleptic character, physical characterization, 
Elemental analysis, Gas chromatography(GC-MS) all these shows the drug  is safe. 
 Therapeutic dose of Thirikadugu dravagam is 5ml Bid. As per OECD guideline 
three dose levels were selected for the study. They are low dose (X), mid dose (5X), high 
dose (10X). X is calculated by multiplying the therapeutic dose (10ml) and the body 
surface area of the rat (0.018). i.e X dose is 0.9 ml/kg, 5X dose is 5ml /kg,10X dose 10 
ml/kg. 
The routine Hematological and Biochemical parameters were observed for sub-
acute and sub-chronic study. The was no significant change in Hematological and 
Biochemical parameters. Histopathology studies did not reveal any abnormal 
macroscopic changes.  
The pharmacological Activity bronchodilator, Anti-histaminic and Anti-
inflammatory activity shows satisfied results. There is no toxicity on administration. 
Thirikadugu dravagam  seems to be safe on animal  experimentation, Studies may 
carried out further for clinical evaluation. 
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               2. AIM AND OBJECTIVES 
 Aim 
 To evaluate the Safety and Pharmacological Profile of the Test Drug 
“THIRIKADUGU DRAVAGAM’’ in Animal Models. 
Objective 
Review of various information relevant to the study from Siddha and modern 
literature. 
Preparation of the drug according to Siddha literature. 
ª Analytical study of  the  prepared drug  
y Organoleptic& physical characterization 
y Chemical analysis to evaluate acidic and basic radicals. 
y TLC&HPTLC Finger print analysis 
y Elemental analysis(ICPOES) 
y Gas chromotography (GS-MC) 
 
ª Toxicity studies: 
y Acute oral toxicity study    OECD – 423 Guideline. 
y 28 day Repeated oral toxicity study   OECD – 407Guideline. 
y 90 days chronic  toxicity study  OECD – 408 Guideline 
 
ª Pharmacological activities in animal models: 
 
y Bronchodilator activity ( Isolated tracheal chain preparation method)     
y Anti-histaminic activity of Thirikadugu dravagam in vivo 
y Anti-inflammatory activity (Carageenan induced paw odema)            
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3.  MATERIALS AND METHOD 
STANDARD OPEATIVE PROCEDURE: 
 Drug selection 
               In this research work Thirikadu dravagam, a poly herbal formulation have been 
selected as a trial drug from the Siddha literature “Yaakobu vaithiya chinthamani 700” 
Third edition-1992, Written by : S.P.Ramachandiran 
Ingredients 
CHUKKU -    Zinngiber officinale  8 palam (280 g) 
MILAGU -   Piper nigrum   8 palam (280 g) 
THIPILLI -    Piper longum   8 palam (280 g) 
ELAM  -    Eletaria cardamomum  8 palam (280 g) 
SEERAGAM -    Cuminum cyminum  8 palam (280 g) 
OMAM  -    Carum copticum   8 palam (280 
Source of collection 
         Drugs were purchased from authorized raw drug shop in Parrys, Chennai. 
Identification and Authentication of the drug 
All the plant materials were identified and authenticated by the Botanist, 
Department of Gunapadam, National Institute of Siddha. 
Dravagam 
Dravagam or Theeneer is the distilled essence, which contains the volatile 
constituents of the drugs used in the preparation, in a medium of water and is equivalent 
to “ aqua” or water of the western pharmacopoeia. 
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PURIFICATION PROCESS 
Purification of chukku 
         Chukku was purified by removing the outer layer and soaking in the limestone water 
for three hours. 
Purification of Milagu 
        Milagu was purified by soaking it in karisalai juice for 7 times, then it was dried. 
Purification of Thipili 
        Thipili was purified by soaking it in kodiveli decoction for three hours and then it 
was dried. 
Purification of Elam 
       Elam was purified by little fried. 
Purification of seeragam 
        Seeragam was purified by soaking it in limestone water for three hours and then it 
was dried. 
Purification of Omam 
        Omam was purified by soaking it in limestone water for three hours and then it was 
fried 
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INGREDIENTS  OF THIRIKADUGU DRAVAGAM 
Chukku                                                                 Milagu
                       
            
 
 
 
 
             Thipilli                                                                  Elam 
           
      
      
 
 
 
 
 
Seeragam        Omam                                   
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Method of preparation 
 
      Raw drugs were purified as per Siddha text, and make them into coarse powder 
individually, and mixed together and transfer the powder into vessel. 
   Purified powder was soaked in water for three days and then subjected into 
distillation  process by vaaluka yanthiram. 
 Finally dravagam was collected and stored in a container. 
                                      
 
Labeling 
     Name of the preparation   :    THIRIKADUGU DRAVAGAM 
     Date of preparation           :    8/6/2015 and 15/2/2016 
     Dose                                  :    5ml 
     Adjuvant / vehicle            :    water 
     Indication                          :    kasam, kshayam, ushnavaayu 
     Date of expiry                   :   1 year from date of preparation 
 
Therapeutic administration of drug 
Form of drug                    :   Liquid form 
Route of administration   :   oral 
  
 
 
 
Review of literature 
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4.1  REVIEW OF LITERATURE 
Gunapadam review 
Rf;F 
NtW ngah;fs;   : mUf;fd;> mjfd; >MHj;ufk;> cgFy;yk;>  cyh;e;j ,Q;rp>            
;                  nrsgh;zk;;;,  Rz;b nrhz;b> fLgj;jpuk;. 
gad;gLk; cWg;G : fpoq;F 
  Rit  : fhh;g;G 
jd;ik : ntg;gk; 
gpupT  : fhh;g;G   
nra;if 
ntg;gKz;lhf;fp 
grpj;j z;b 
mfl;Ltha;tfw;wp 
nghJFzk; 
#iyke;jk; neQ;nrhpg;G>Njhlkg; gk;koiy 
%yk; ,iug;gpUky; %f;FePh;- thyfk; 
Njhlkjp rhuj; njhlh;thj Fd;kePh;j; 
Njhl Mkk;Nghf;FQ; Rf;F. 
                         (mfj;jpau; Fzthflk ;) 
Rf;fpdhy; nrupahik> ,iug;G> ,Uky;> tapw;Wg;gprk; Nghk;. 
Rf;F NrUk; kUe;Jfs; 
 thu;gj;jpahjp R+uzk; 
 rptij R+uzk; 
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                        kpsF 
NtW ngau;fs;    : kiyahsp> rUkge;jk;> Nfhsfk;> FWkpsF 
gad;gLk; cWg;G  : tpij>nfhb 
Rit     : ifg;G>fhu;g;G 
jd;ik    : ntg;gk; 
gpupT     : fhu;g;G 
nra;if 
mfl;Ltha;tfw;wp 
Kiwntg;gfw;wp 
ntg;gKz;lhf;fp 
nghJFzk; 
   rPjRuk; ghz;L rpNyj;kk; fpuhzp Fd;kk; 
 thjk; mUrp gpj;jk;> kh%yk;- XJre;ep  
 ahrkg]; khuk; mld; Nkfk; fhrkpit 
 ehrq; fwp kpsfpdhy;  
                                            (mfj;jpau; Fzthflk ;)  
      kpsfpdhy; ,Uky;> fgf;Fw;wq;fs; Nghk;. 
 
kpsF NrUk; kUe;Jfs; 
RthrFNlhup R+uzk; 
fz;lq;fj;jup R+uzk; 
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jpg;gpyp 
NtW ngau;fs;   : Mu;fjp> fhkd;> Flhup> NfhioaWf;fp> fzk;> mk;G> MjpkUe;J 
gad;gLk; cWg;G : fha;>muprp 
     Rit    : ,dpg;G 
     jd;ik    : jl;gk; 
     gpupT     : ,dpg;G 
nra;if 
mfl;Ltha;tfw;wp 
      ntg;gKz;lhf;fp 
nghJFzk; 
,Uky; Fd;kk; ,iug;G fag;gpzp 
  <is ghz;L re;ahrk; mNuhrfk; 
  nghUky; Cij rpug;gpzp %u;r;irNeha; 
                        (mfj;jpau; Fzthflk;) 
<is> ,Uky;> ,iug;G> fLikahd Iag;gpzpfis mfw;wp> clw;F 
td;ikia mspj;jpLk;.   
 
jpg;gpyp NrUk; kUe;Jfs; 
jpg;gpypahjp Ruzk; 
 RuGq;f tpy;thj ,sfk; 
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Vyk; 
NtW ngau;fs;  : MQ;rp>Nfhuq;fk;> Jb 
Rit    :  fhh;g;G 
jd;ik   : ntg;gk; 
gpupT     : fhh;g;G 
nra;if 
mfl;Ltha;tfw;wp 
ntg;gKz;lhf;fp 
grpj;jPJhz;b 
nghJ Fzk; 
gz;il ntf;if tpjhfNeha; fhrKk; 
ghOQ; Nrhkg; gpzpte;J el;lKk; 
mz;il aPistd; gpj;jk; ,itf;nfy;yhk; 
My khq;fko; Vy kUe;Nj. 
                           (Njud; Fzthflk;)
  
,J njhz;il Neha;fisAk;> ,Uky;> neQ;rpd; Nfhiofl;L ,tw;iw Nghf;Fk; 
 
Vyk; NrUk; kUe;Jfs ;  
     fz;lhj;jpup ,sfk; 
     fw;G+uhjp R+uzk; 
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rPufk; 
NtW ngau;fs;   : Mir> rPup> cgFk;ggPrk;> Jj;jrhk;gyk;> ew;rPup> gpj;jehrpdp>  
   Nkj;jpak;> NgrdFNlhup 
gad;gLk; cWg;G : tpij 
Rit     : fhu;g;G>,dpg;G 
jd;ik   : jl;gk; 
gpupT     : ,dpg;G 
nra;if 
mfl;Ltha;tfw;wp 
ntg;gKz;lhf;fp 
grpj;jPJhz;b 
Jtu;g;gp 
nghJFzk; 
     gpj;jnkDk; ke;jpupiag; gpd;dg; gLj;jpatd; 
     rj;JUit Ae;Jwe;J rhjpj;J- kj;jndDk; 
     uhridA kPntd;W ez;igg; gygLj;jp 
     NghrdF NlhupnrAk; Nghu;. 
                          (Njud; ntz;gh)  
      ,jdhy; ,iug;G Nghk;. 
 
rPufk; NrUk; kUe;Jfs; 
,ytq;fhjpr; R+uzk; 
jpg;gpyp nea; 
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                        Xkk; 
NtW ngau;fs; : mrNkhjk;> jPg;gpak; 
gad;gLk; cWg;G  : tpij 
Rit    :  fhu;g;G> 
jd;ik   :  ntg;gk; 
gpupT     : fhh;g;G 
nra;if 
      mfl;Ltha;tfw;wp 
      ntg;gKz;lhf;fp 
      grpj;jPJhz;b 
      cukhf;fp 
nghJFzk; 
   rPjRuk; fhrk; nrupahke; jk;nghUky; 
 Ngjpapiur; ry;fLg;G Nguhkk;- xjpUky; 
   gy;nyhLgy; %yk; gfkpitNeh nad;nrANkh 
 nrhy;nyhLNghk; Xkndr; nrhy; 
                       (mfj;jpau; Fzthflk;) 
,jdhy; IaRuk;> ,Uky;> ,iug;G> Nghk; 
 
Xkk; NrUk; kUe;Jfs; 
rq;rPtp jPePu; 
rpj;jhjp ,sfk; 
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4.2 LITERATURE REVIEW 
Botanical review 
CHUKKU 
Botanical name   :  Zingiber officinale 
Family                  :  Zingiberaceae 
Vernacular name 
 English    :     Ginger 
 Hindi       :     Adrak 
 Tamil        :     chukku 
Parts used 
Rhizome  
Organoleptic Characters 
Odour    :  Aromatic  
Taste      :  spicy, pungent, hot, biting 
Action 
 Carminative 
 Stomachic 
 Stimulant 
 Digestive 
Chemical constituents 
y   -curcumene   
y   -phellandrene, 
y   calamene 
14 
 
Phytochemical property 
The dried rhizome of ginger contains 1-4% volatile oils, these are  the aromatic 
principle  include, zingiberene , bisabolene . 
Medicinal uess 
y The herb is an excellent remedy for strengthening and healing the respiratory 
system fighting often colds and flu, removing congestion, soothing sore 
throats. 
y It is recommended during pregnancy for treating morning sickness and 
digestive problem. 
y Useful for Belching, Laryngitis and Rheumatoid arthritis. 
Lateral Articles 
y A study done in France the researchers found that (6) gingerol, a major constituent 
of ginger was sufficient to supports Eosinophilia. 
y This suggested that ginger could suppress TH2- mediated immune response and 
might thus provide a possible therapeutic application in ‘‘Allergic asthma” 
y A study in Canada shows that ginger inhibits airway contraction and associate 
Ca(2+) signalling possibly via blockage of plasma membrane Ca(2+) channels, 
thus reiterating its effectiveness in treating respiratory illness.  
Safety Evaluation of Trikatu 
         Acute and sub-acute toxicity study of Trikatu, a generic herbal formulation of 
Indian system of medicine was carried out in Charles foster rats for safety profiling. In 
acute toxicity 2,000mg/kg once was well tolerated by experimental animals and no 
changes were observed in mortality, morbidity, gross pathology, gain in weight, 
haematological and biochemical parameters. 
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MILAGU 
Botanical name   :   Piper nigrum 
Family                  :    Piperaceae 
Vernacular name 
    Tamil        :  Milagu 
            English      :  Black pepper 
            Hindi         :   kalimirch 
Part used              :    Fruits 
Organoleptic characters 
  Taste         :  Bitter, hot 
  Nature      :  Hot 
 Division  :  Hot 
Action 
Carminative, Digestive, Stomachic 
Chemical constituents 
  Seed       :  Amidepipericide , alkaloid piperine , oleoresin, volatile oils 
   Stem        :  piperine , - sitostrol ,sesquisabinene , Hentriacontane 
Medicinal Uses 
y Black pepper is an best anti-dote. 
y Useful in Asthma, Bronchitis, Epilepsy. 
 Lateral articles  : Oral administration of piperine in different propotion of mice 
suppressed and reduce the infiltration of eosinophilia, hyper responsiveness and 
inflammation due to the suppression of the production of histamine  interleukin-5, 
immunoglobulin E and interleukin.                                                                                                           
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THIPPILI 
Botanical name        :   Piper longum 
Family                     :    Piperaceae 
Vernacular name 
            English :  Indian long pepper 
    Hindi  :   Pipli 
  Tamil  :   Thipilli 
Parts used                :  Roots and Fruits 
Organoleptic characters 
Taste     :   Sweet 
Nature  :   Hot 
Division :  Sweet 
Action 
  Carminative, Expectorant, Digestive 
Chemical constituent 
y piperine  
y piperlongumine 
y piplartine 
Medicinal uses 
Piper longum is most commonly used for its benefits in respiratory and digestive 
systems. Decoction of immature fruits and roots is used in chronic bronchitis and asthma.  
   
In Vivo and in vitro Anti-asthmatic studies of Piper  : The extract of piper 
longum 100µgml significantly inhibited the histamine induced Broncho constriction  of 
isolated guinea pig ileum. 
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ELAM 
Botanical name   :  Elettariacardamomum 
Family                 :  Zingiberaceae 
Vernacular name 
Tamil      :  elakkaay 
Hindi       :  elachi 
Part used            :  Seed  
Organoleptic characters 
 Taste      :  Hot 
 Nature    :  Hot 
 Division  :  Hot 
Action 
  Carminative, Stomachi, Stimulant 
Chemical constituent 
y Oleum  
y Cardamoni  
y Sabinene  
y d – -terpineol  
y Methyl eugenol. 
Medicinal uses 
Seeds are used to prevent Halitosis , indigestion , and nausea 
  It is also used to common cold,cough,bronchitis, fever, inflammation of mouth 
and pharynx. 
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SEERAGAM 
Botanical name   : cuminum cyminum 
Family                :  Apiaceae 
Vernacular name 
           Telugu    :    jilaka 
Hindi      :   shaijira 
Tamil      :   Seeragam 
Part used           :   ( Seeds) fruit  
Organoleptic characters 
Taste     :  Hot, sweet 
Nature   :  cold 
Division :  sweet 
Action 
 Carminative, Astringent, Stomachic, Anti- spasmodic 
 Chemical constituents 
y Pinene 
y Sabinene 
y Myrcene 
Medicinal uses  
   It is very useful in digestive disorders like biliousness, morning sickness. 
Lateral article 
   A recent study showed bronchodilator effect in guinea pig tracheal chain using 
the oil of cuminum cyminum. 
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OMAM 
Botanical name  :  Carum copticum 
Family                :   Apiaceae 
Vernacular name 
English    :   The bishops weed 
Hindi       :   Ajvayam 
Part used          :    Seeds 
Organoleptic characters 
 Taste     :  Hot, bitter, pungent 
 Nature   :  Hot 
 Division :  Hot 
Action 
Stomachic, Anti-spasmodic, Carminative 
Chemical constituents 
y Thymol 
y Terpine 
y Carvacol 
Medicinal uses  
y It is used for therapeutic effect including bloating, fatigue, diarrhea, abdominal 
tumors, and respiratory distress. 
y It has benefits such as anti-fungal, antioxidant, anti-parasitic , and hypo-lipidemic 
effect. 
y  Lateral articles ; Carum copticum has a relative bronchodilator effect on 
asthmatic airways which was compared to theophylline. 
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4.3   PHARMACEUTICAL REVIEW 
 Dravagam or Theeneer is the distilled essence, which contains the volatile 
constituents of the drugs used in the preparation, in a medium of water and is equivalent 
to “ aqua” or water of the western pharmacopoeia. 
The term  Dravagam or Theeneer denotes the acceptable aromatic nature of the 
drug and indicates that it is in the Aquous state. 
Preparation 
The preparation of Dravagam or Theeneer involves the efficient distillation of 
water soaked coarse powders of the drugs. The volatile principles which are evolved 
admixture with water vapor from the still are condensed and taken. 
Equipment required 
Bottle of large capacity of handle the distillate. 
An assembly of apparatus as described below or modifications thereof for 
distillation 
Process of preparation 
 The drugs are crushed into a coarse powder and soaked in the prescribed quantity 
of water, for about a day or at least over night and then charged into the still, along with 
the water. 
            The lid is tightly set in and around to prevent leakage of vapors. For the purpose 
of sealing a cloth ribbon with a paste of black gram is used. Heat is applied to the drug 
mixture and distillate is collected in bottles, and then the whole condensate from one 
charging is thoroughly mixed, because the portions that had condensed later would be a 
weaker in concentration.  A Continuous water current should be maintained in the 
condenser. 
Storage 
Dravagam or Theeneer should be stored in air tight containers of glass. If kept 
open, the volatile active principles will be lost by evaporation. Dravagam or Theeneer is 
administered along with an equal volume of water. 
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5 .  ANALYTICAL STUDY OF THIRIKADUGU  DRAVAGAM 
 
Analytical study of the drug brings the validation to be used as a medicine by 
subjecting the drug to many analysis and determining the quality and effectiveness. 
Analytical study includes such as organoleptic characterization, Physical characteristic, 
TLC and HPTLC Finger print analysis also to assess the active principles and element 
present in the drug. Thus standardization brings the efficacy and potency of the drug.  
As per AYUSH Protocol for standardization, the following parameters were evaluated. 
y Organoleptic characters 
y Physical characterization 
y Chemical analysis 
y TLC&HPTLC Finger print analysis 
y Elemental analysis (ICP-OES) 
y Gas –Chromotography (GS-MC) 
5. 1 Organoleptic character of Thirikadugu Dravagam 
Colour   :  The medicine was taken in watch glasses and placed against white back     
ground in white   tube light. It was observed for its colour by naked eye. 
Odour  :  The medicine was smell individually. The time interval among two smelling 
was kept 2 minutes to nullify the effect of previous smelling. 
 Taste :   Small amount of Thirikadugu dravagam was kept over the tip of the tongue  
5.2 Physical properties 
 i)   Determination of PH 
    Five grams of Thirikadhugu dravagam was weighed accurately and placed in clear 
l00ml beaker. Then  50 ml distilled was added to it and dissolve well. After 30 min it was 
then applied into Ph metera as standard buffer solution of 4.0, 7.0,9.2. Repeated the test 
four and average was recorded. 
  
 
 
 
Chemical analysis 
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5.2 CHEMICAL ANALYSIS OF THIRIKADUGU DRAVAGAM 
The chemical analysis of Thirikadugu  dravagam  was carried  out in Bio-chemistry 
lab, National institute of siddha. 
S.No EXPERIMENT OBSERVATION INFERENCE 
1.  Physical Appearance of extract Pale yellow  in colour  
2. Test for Silicate 
a. A 2ml of the sample was shaken 
well with distilled water. 
Completely soluble 
 
 
Absence of Silicate 
 
 
3. Action of Heat: 
A 2ml of the sample was taken in a 
dry test tube and heated gently at first 
and then strong. 
 No White fumes 
evolved. 
No brown fumes 
evolved. 
Absence of 
Carbonate 
Absence of Nitrate. 
 
4. Flame Test: 
  A 2ml of the sample was made into a 
paste with con. HCl in a watch glass 
and introduced into non-luminous part 
of the Bunsen flame. 
No bluish green 
flame 
 
Absence  of copper 
 
 
5. Ash Test: 
A filter paper was soaked into a 
mixture of extract and dil. cobalt 
nitrate solution and introduced into the 
Bunsen flame and ignited. 
No Appearance of 
yellow colour flame 
 
 
 
Absence of sodium 
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Preparation of Extract: 
5ml of sample was taken in a 250ml clean beaker and added with 50ml of distilled 
water. Then it is boiled well for about 10 minutes. Then it is cooled and filtered in a 
100ml volumetric flask and made up to 100ml with distilled water. This preparation is 
used for the qualitative analysis of acidic/basic radicals and biochemical constituents in it. 
 
S.N EXPERIMENT OBSERVATION INFERENCE 
 I. Test For Acid Radicals   
1. Test For Sulphate: 
a.2ml of the above prepared extract was taken 
in a test tube to this added 2ml of 4% dil 
ammonium oxalate solution 
No cloudy 
appearance 
Absence of 
Sulphate 
2. Test For Chloride: 
2ml of the above prepared extracts was added 
with 2ml of dil-HCl is added  
until the effervescence ceases off.. 
Cloudy 
appearance 
present. 
 
Presence of 
Chloride  
 
3. Test For Phosphate: 
2ml of the extract were treated with 2ml of 
dil.ammoniummolybdate solution and 2ml of 
con.HNo3 
No cloudy 
yellow 
appearance 
present  
Absence of 
Phosphate  
 
4. 
 
Test For Carbonate: 
2ml of the extract was treated with 2mldil. 
Magnesium sulphate solution. 
No cloudy 
appearance. 
Absence of  
carbonate 
24 
 
5 Test For Nitrate: 
1gm of the extract was heated with copper 
turning and concentrated H2So4 and viewed the 
test tube vertically down. 
No Brown gas 
is evolved 
Absence of 
nitrate 
6. Test For Sulphide: 
1gm of the extract was treated with 2ml of con. 
HCL 
No rotten egg 
smelling gas is 
evolved 
Absence of 
sulphide 
7. Test For Fluoride & Oxalate: 
2ml of extract was  added with 2ml of dil. 
Acetic acid and 2ml dil.calcium chloride 
solution and heated. 
No cloudy 
appearance. 
Absence of 
fluoride and 
oxalate 
 
8. 
Test For Nitrite: 
3drops of the extract was placed on a filter 
paper, on that-2 drops of dil.acetic acid and 2 
drops of dil.Benzidine solution is placed. 
No 
characteristic 
changes 
Absence of 
nitrite 
9. Test For Borate: 
2 Pinches (50mg) of the extract was made into 
paste by using dil.sulphuric acid and alcohol 
(95%) and introduced into the blue flame. 
No 
Appearance of 
bluish green 
colour 
Absence of 
borate 
II. Test For Basic Radicals 
1. Test For Lead: 
2ml of the extract was added with 2ml of 
dil.potassium iodine solution. 
No Yellow 
precipitate is 
obtained 
 
Absence of lead 
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2. Test For Copper: 
a. One pinch (25mg) of extract was made into 
paste with con. HClin a watch glass and 
introduced into the non-luminuous part of the 
flame. 
No blue 
colour 
precipitate 
Absence of    
copper 
3. Test For Aluminium: 
To the 2ml of extract dil.sodium hydroxide was 
added in 5 drops to excess. 
No 
characteristic 
changes 
Absence of    
Aluminium. 
 
4. Test For Iron: 
a. To the 2ml of extract add 2ml of 
dil.ammonium solution 
No Red 
colour 
appeared 
Absence of Iron 
 
5. 
 
 
Test For Zinc:  
To 2ml of the extract dil.sodium hydroxide 
solution was added in 5 drops to excess and 
dil.ammonium chloride is added.  
NoWhite 
precipitate is 
formed 
Absence of 
Zinc 
6. Test For Calcium:  
2ml of the extract was added with 2ml of 4% 
dil.ammonium oxalate solution  
Cloudy 
appearance 
and white 
precipitate 
obtained 
presence of 
calcium 
 
7. Test For Magnesium:  
To 2ml of extract dil.sodium hydroxide solution 
was  added in drops to excess. 
No  White 
precipitate is 
obtained 
Absence  of 
magnesium 
8. Test For Ammonium: 
To 2ml of extract 1 ml of Nessler's reagent and 
excess of dil.sodium hydroxide solution are 
added. 
No  Brown 
colour 
appeared 
Absence  of 
ammonium 
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9. Test For Potassium: 
A pinch (25mg) of extract was treated of with 
2ml of dil.sodium nitrite solution and then 
treated with 2ml of dil.cobalt nitrate in 30% 
dil.glacial acetic acid. 
No Yellow 
precipitate is 
obtained 
Absence of 
potassium 
10. Test For Sodium: 
2 pinches (50mg) of the extract is made into 
paste by using HCl and introduced into the blue 
flame of Bunsen burner. 
No yellow 
colour flame 
evolved. 
 
Absence of 
sodium 
11. Test For Mercury:  
2ml of the extract was treated with 2ml of 
dil.sodium hydroxide solution.  
No Yellow 
precipitate is 
obtained 
Absence of 
Mercury 
12. Test For Arsenic:  
 2ml of the extract was treated with 2ml of 
dil.sodium hydroxide solution. 
No  Brownish 
red precipitate 
is obtained 
Absence of 
arsenic 
III. Miscellaneous 
1.
  
Test For Starch: 
2ml of extract was treated with weak dil.Iodine 
solution  
No Blue colour 
developed 
 
Absence of 
starch 
 
2.
  
Test For Reducing Sugar: 
5ml of Benedict's qualitative solution was taken in 
a test tube and allowed to boil for 2 minutes and 
added 8 to 10 drops of the extract and again boil it 
for 2 minutes. The colour changes are noted. 
No Brick red 
colour is 
developed 
Absence of  
reducing sugar 
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3. Test For The Alkaloids: 
a) 2ml of the extract was treated with 2ml of 
dil.potassium lodide solution. 
b)  2ml of the extract was treated with 2ml of dil. 
picric acid. 
c)  2ml of the extract was treated with 2ml of dil. 
phosphotungstic acid. 
 
Yellow colour 
developed 
 
 
Presence 
of Alkaloid 
 
4.
  
Test For Tannic Acid:  
2ml of extract was treated with 2ml of dil.ferric 
chloride solution  
No Blue-black 
precipitate is 
obtained 
Absence of 
Tannic acid 
5.
  
Test For Unsaturated Compound: 
To the 2ml of extract 2ml of dil.Potassium 
permanganate solution is added.  
Potassium 
permanganate 
is not 
decolourised 
Absence of 
unsaturated 
compound 
6.
  
Test For Amino Acid: 
2 drops of the extract was placed on a filter paper 
and dried well. 20ml of Burette reagent is added. 
No violet 
colour 
Absence of 
amino acid 
 
7. 
Test For Type Of Compound: 
2ml of the extract was treated with 2 ml of 
dil.ferric chloride solution.  
No green and 
red colour 
 
No Violet 
colour 
developed 
 
 
 
No Blue colour 
developed. 
Absence of 
quinolepinephr
inepyrocatecho
antipyrine 
Aliphatic 
amino acid and 
meconic acid. 
Apomorphine 
salicylate and 
Resorcinol are 
absent 
Morphine,Phen
ol cresol and 
hydrouinone 
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5.4   TLC/HPTLC FINGER PRINT ANALYSIS 
    
Thin layer chromatography (TLC) is a chromatographic technique used to 
separate the components of a mixture using a thin stationary phase supported by an inert 
backing. It may be performed on the analytical scale as a means of monitoring the 
progress of a reaction, or on the preparative scale to purify small amounts of a compound. 
 TLC/HPTLC is an analytical tool widely used because of its simplicity, relative 
low cost, high sensitivity, and speed of separation. TLC/HPTLC functions on the same 
principle as all chromatography: a compound will have different affinities for the mobile 
and stationary phases, and this affects the speed at which it migrates. The goal of 
TLC/HPTLC is to obtain well defined, well separated spots. 
Retention Factor 
After a separation is complete, individual compounds appear as spots separated 
vertically. Each spot has a retention factor (Rf) which is equal to the distance migrated 
over the total distance covered by the solvent. The Rf formula is 
Rf  = distance traveled by sample /distance traveled by solvent The Rf value 
can be used to identify compounds due to their uniqueness to each compound.  When 
comparing two different compounds under the same conditions. The compound with the 
larger Rf value is less polar because it does not stick to the stationary phase as long as the 
polar compound, which would have a lower Rf value 
TLC and HPTLC Methodology 
10ml of the given sample soaked in 10ml of 95%ethyl alcohol kept it overnight. 
Then 40ml of ethyl acetate added. Ethyl acetate layer was separated and dried over 
anhydrous sodium sulphate, filtered and concentrated to 5ml at room temperature. 45 
µl,50 µl of the above solution were applied on Merck Aluminium plate pre-coated with 
silica gel 60 F 254  of thickness using ATS-IV. The plate was developed in Toluene:  Ethyl 
acetate (1:2). The plate was dried and visualized in UV 254 nm and UV 366nm and 
photos were taken. The plate was scanned at 254 nm before dipping. Then the plate was 
dipped in vanillin – sulphuric acid and heated at 105°C till the Colour of the spots 
appeared and photos were taken.      
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4.5   ELEMENTAL ANALYSIS 
INDUCTIVELY COUPLED PLASMA OPTICAL  EMISSIOS  SPECTROMETRY 
   ICP-OES is a trace level elemental analysis that uses the  emission spectra of a 
sample to identify and qualify the elements present. The experimental procedure was 
done at SAIF, IIT Madras.chennai-36. 
Introduction 
 The element composition of a sample is often an important part of the 
information needed to assess its properties. Hence there is a need for scientific 
instrumentation like ICP-OES which plays a pivotal role in the determination of these 
elements. ICP-OES is widely employed for the estimation of metals and metallolids at 
trace, minor and major concentration. 
Principle  
In this technique, the high temperature plasma source atomizes the sample and 
excites the atoms resulting in emission of photons. The atoms of each element in the 
sample emit specific wavelength of light. The emission spectrum from the plasma is 
dispersed by an optical spectrometer, so that intension of the individual wavelength can 
be measured. The number of photos emitted is directly proportional to the concentration 
of the element.  The photos may be detected either sequentially or simultaneously. 
Quantitative analysis is achieved by measuring the intensity of these specific wavelength 
and after performing the calibration using known standards. 
Identifying the presence of emission at the wavelength characteristic of the 
element of interest obtaining quantitative information i.e  how much of an element is in 
sample can be accomplished using plots of emission intensity versus concentration called 
calibration curves.     
ICP-OES  Operating conditions 
Rf  frequency 40 M Hz 
Range 165-782nm 
Detection time up to ppm level using SCD detector 
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Sample preparation – Microwave Digestion 
y  Weight 0.25 g of test sample and transfer into a liner provided with instrument. 
y Slowly add 9ml of Nitric acid or Sulphuric acid such that no piece of sample 
sticks on the slide. 
y Mix thoroughly and allow reacting for few minutes. 
y Place the liner in the vessel jacket. 
y Close the screw cap hand- tight in clockwise direction. 
y Seal the vessel and placed in the rotor fixed in microwave. 
y Set temperature to 180°C for 5 minutes, hold at 180°C for least 10 minutes.                                                                                                                             
Allow the vessels to cool down to a vessel interior temperature below 60°C and to 
a vessel surface temperature (IR) below 50°C before removing the rotor. 
y The digested sample was made upto 100ml  with Millipore water. 
y If visible insoluble particles exist, solution could be filtered through whatmann 
filter paper. 
y Transfer the digested solution into plastic containers and label them properly.        
 
                
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
The analytical results of Elemental analysis in Thirikadugu dravagam using ICP-
OES are showed in table 5.5 
 
*** IIT Saif Madras 
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5.6 GAS CHROMOTOGRAPHY : (GC-MS) 
Gas chromatography is a chromatographic separation technique based on the 
difference in the distribution of species between two non- miscible phase in which the 
mobile phase is a carrier gas moving through or passing the stationary phase contained in 
a column. It is applicable to substances or their derivatives, which are volatilized under 
the temperatures employed. 
GC is based on mechanism of adsorption, mass distribution or size exclusion. 
METHOD 
    Equilibrate the column, the injector and the detector at the temperatures and the 
gas flow rates specified in the monograph until a stable baseline is achieved. Prepare the  
test solution ( S) and the reference solution (S) as prescribed. The solution must be free 
from solid particles. 
GC-MS SPECTROMETER 
 
    The JEOL GCMATE II GC-MS with Data system is a high resolution, double focusing 
instrument. Maximum resolution: 6000 Maximum calibrated mass: 1500 Daltons. Source  
options: Electron impact (EI); Chemical ionization (CI) .    
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Applications 
y Structural elucidation of organic compounds. 
y Mechanistic study of fragmentation process under mass spectrometric condition. 
y Molar mass and structural analysis of small biomolecules. 
 
 Instrument   name :   JEOL GC MATE II 
 Front inet temp : 220 degree c 
 Column  :  HP 5 Ms 
 Carrier gas  :   high pure helium  
 Flow rate  : 1 ml /min  
 Oven temp  :  50 to 250 @ 10 deg / min 
 Ion chamber tem :  250 deg c 
 GC interface temp :  250 deg c 
 Mass analyzer :  quadrupole with double  focusing mass analyzer, 
 Detector  : Photon multiplier tube
 Scam   :  50 to 600 amu 70ev electron impact  ionization  
 
 
 
 
*** IIT Saif Madras 
  
 
 
 
Toxicity studies 
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6.  TOXICOLOGICAL EVALUATION OF THIRIKADUGU 
DRAVAGAM ON WISTAR ALBINO RATS 
Plan work :  
    Safety is a fundamental principle in the provision of traditional medicines and 
herbal products for health care and a critical. 
Component of quality control. OECD guidelines provide practical and technical 
guidance for monitoring the safety of traditional medicines within Pharmacovigilance 
systems. The safety monitoring of traditional medicines is compared and contrasted with 
that of other Medicines,   currently undertaken in the context of the WHO International 
Drug perspective. 
Scope of work:  
Monitoring Programme. While there are regulatory and cultural differences in the 
preparation and use of different types of medicines, they are all equally important from a 
pharmacovigilance 
Assurance of safety, quality and efficacy of Indian System of Medicines (ISM) is 
the key issue that needs to be addressed while conducting toxicity studies. It is an 
essential step, which will strengthen the acceptance of Siddha medicines by scientific 
community. Information of toxicity and adverse effects of these formulations are lacking. 
Some of the formulations are proved to be effective in various animal studies and many 
more are yet to be tested.  
 Hence, the present study was carried out to evaluate the Preclinical toxicity 
studies of  THIRIKADUGU DRAVAGAM  in animal models. 
The following studies were carried out on THIRIKADUGU DRAVAGAM 
y Acute Oral toxicity – OECD 423 
y Repeated dose 28 Days  Oral Toxicity Study – OECD 407 
y Repeated dose 90 Days  Oral Toxicity study-OECD 408 
 
*** KK. College of Pharamacy 
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ACUTE AND SUBACUTE  TOXICITY STUDIES  OF  THIRIKADUGU 
DRAVAGAM  ON WISTAR ALBINO  RATS 
ACUTE ORAL TOXICITY-EXPERIMENT PROCEDURE:  
Introduction:  
Acute toxicity studies were carried out according to the OECD (Organization of 
Economic Co-operation and Development) guidelines 423. Healthy female wistar Albino 
rats, weighing 150–200 g, were selected and oral administration of the single doses of 
Thirikadugu Dravagam  with water. 
All the protocols and the experiments conducted in strict compliance according to 
ethical principles and guidelines provided by committee for the purpose of control and 
supervision of experiments on animals. Animal experimentation and protocol were 
approved by Institutional animal ethical committee. (KKCP/2015/029) 
Animals and dose levels:  
 Healthy young adult animals of commonly used laboratory used. Three and 12 
weeks old and its weight should fall in an interval within ±20 % of the mean animals 
weight of any were used for each step. Each animal, at the commencement of its dosing, 
should be between 8 previously dosed animals.  
  The dose level used as the starting dose was selected from fixed levels 
10ml/kg body weight. Dose for animal is freshly prepared shortly prior to administration. 
The available information suggest that highest starting dose level 10ml/kg body weight, 
so the trial or limit test was conducted. The time interval between treatment groups is 
determined by the onset, duration, and severity of toxic signs. 
Administration of doses:  
Thirikadugu Dravagam was administered as a single oral dose by gavage using a 
feeding needle. Animals were fasted prior to dosing. Following the period of fasting, the 
animals were weighed and then the test substance was administered. After the substance 
has been administered, food was withheld for a further 3-4 hours. The principle of 
laboratory animal care was followed. Observations were made and recorded 
systematically and continuously observed as per the guideline after substance 
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administration An oral (p.o) dose of 1mL/kg bw, 5ml/kg bw and 10ml/kg bw was 
administered step by step according to the guidelines. The general  behaviors of the rats 
were continuously monitored for 1 hr after dosing, periodically during the first 24 h (with 
special attention given during the first 4 hours and then daily thereafter, for a total  of  
14days. 
 Changes in the normal psychomotor activity and external morphology and their 
body weights were monitored periodically before dosing and the time at which signs of 
toxicity or mortality were recorded. 
 The visual observations included skin changes, morbidity, aggressively, 
sensitivity to sound and pain, as well as respiratory movements. They were deprived of 
food, but not water 12 hr prior to the administration of the test substance. Finally, the 
number of survivors was noted after 24 h and these animals were then maintained for a 
further 14 days and observations made daily. The toxicological effect was assessed on the 
basis of mortality.  
OBSERVATIONS:  
 Animals were observed individually after dosing at least once during the first 30 
minutes, periodically during the first 24 hours, with special attention given during the first 
4 hours, and daily thereafter, for a total of 14 days, except where they need to be removed 
from the study and humanely killed for animal welfare reasons or are found dead. It 
should be determined by the toxic reactions, time of onset and length of recovery period, 
and may thus be extended when considered necessary. The times at which signs of 
toxicity appear and disappear are important, especially if there is a tendency for toxic 
signs to be delayed. All observations are systematically recorded with individual records 
being maintained for each animal. Observations include changes in skin and fur, eyes and 
mucous membranes, and also respiratory, circulatory, autonomic and central nervous 
systems, and somato motor activity and behavior pattern. Attention was directed to 
observations of tremors, convulsions, salivation, diarrhea, lethargy, sleep and coma. The 
principles and criteria summarized in the Humane Endpoints Guidance Document taken 
into consideration. Animals found in a moribund condition and animals showing severe 
pain or enduring signs of severe distress was humanely killed. When animals are killed 
for humane reasons or found dead, the time of death should was recorded. 
  
 
 
Repeated dose 28 days oral 
toxicity 
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REPEATED DOSE 28 DAYS ORAL TOXICITY STUDY OF THIRIKADUGU 
DRAVAGAM ON WISTAR ALBINO RATS 
                                      (OECD – 407 guidelines) 
Sub-acute toxicity studies were carried out according to OECD 407 and rats were 
divided into 3 groups of 10 animals (5 male and 5 female). Group I served as control 
(distilled water at the dose of 10ml/kg bw) and Group-II and III were treated with 
Thirikadugu Dravagam at the dose of 5ml and 10ml/kg bw for 28 days. The toxic 
symptoms such as signs of toxicity, mortality and body weight changes were monitored. 
Rats were anesthetized with ether at the end of the treatment period. All rats were 
sacrificed after the blood collection. 
Test Substance : Thirikadugu Dravagam 
Animal Source  : Animal house of King Institute of Preventive Medicine 
Animals : Male and Female Wistar Albino Rats  
Age  : More than 8 weeks 
Acclimatization : Seven days prior to dosing. 
Veterinary examination : Prior to and at the end of the acclimatization period. 
Identification of 
animals 
: By cage number and individual marking on fur. 
Diet : Pelleted feed supplied by Sai meera foods Pvt Ltd, 
Bangalore 
Water  : Aqua guard portable water in polypropylene bottles ad 
libitum. 
Housing & 
Environment 
: The animals were housed in Polypropylene cages provided 
with bedding of husk. 
Housing temperature : Between 20 & 24°C,  
Relative humidity : Between 30% and 70%, 
Dark and light cycle  : Each of 12 hours. 
Duration of the study       :    28 days 
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Justification for Dose Selection: 
The results of acute toxicity studies in rats indicated that Thirikadugu Dravagam 
was non toxic and no behavioral changes were observed up to the dose level of 10ml/kg  
body weight in acute treatment. 
As per OECD guideline three dose levels were selected for the study. They are 
low dose (X), mid dose (5X), high dose (10X). X is calculated by multiplying the 
therapeutic dose (10ml) and the body surface area of the rat (0.018). i.e X dose is 0.9 
ml/kg, 5X dose is 5ml /kg,10X dose 10 ml/kg 
Preparation and  administration of dose:  
Thirikadugu Dravagam was aseptically administered to animals at the dose levels 
of 5ml and 10ml/kg bw. The test substance was freshly used from the drug container. The 
drug was administered for a period of 28 days. The control animals were administered 
water (10ml/kg bw) only. Administration was by oral (gavage), once daily for 28 
consecutive days. 
METHODOLOGY 
Randomization, Numbering and Grouping of Animals: 
 Ten Rats (Five Male and Five Female) in each group randomly divided into three 
groups for dosing up to 28 days. Animal’s acclimatization period of 7 days to laboratory 
conditions prior to the initiation of treatment. Each animal was fur marked with picric 
acid. The females were nulliporous and non-pregnant. 
OBSERVATIONS: 
Experimental animals were kept under observation throughout the course of study 
for the following: 
Body Weight: 
Weight of each rat was recorded on day 0 and at 5 days intervals throughout the 
course of study and at termination to calculate relative organ weights. From the data, 
group mean body weights and percent body weight gain were calculated.  
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Food and water Consumption:  
The quantity of food consumed by groups consisting of ten animals of for 
different doses was recorded at weekly interval. Food consumed per animal was 
calculated for control and the treated dose groups.  
Clinical signs:  
All animals were observed daily for clinical signs. The time of onset, intensity and 
duration of these symptoms, if any, were recorded. 
Mortality:  
All animals were observed twice daily for mortality during entire course of study  
 
TERMINAL STUDIES: 
Laboratory Investigations:  
Following laboratory investigations were carried out on day 29 in animals’ fasted 
over-night. On 29th day, the animals were fasted for approximately 18 h, then slightly 
anesthetized with ether and blood samples were collected from the retro-orbital plexus 
into two tubes: one with EDTA for immediate analysis of haematological parameters, the 
other without any anticoagulant and was centrifuged at 4000 rpm at 4 °C for 10 minutes 
to obtain the serum. Serum was stored at 20 °C until analyzed for biochemical 
parameters. 
Haematological Investigations:  
Blood samples of control and experimental rats were analyzed for hemoglobin 
content, total red blood corpuscles (RBC), white blood corpuscles (WBC) count, Mean 
corpuscular volume (MCV) and packed cell volume (PCV). From the estimated values of 
RBC count (millions/mm3) and PCV (volumes percent), mean corpuscular volume 
(MCV) was calculated.  
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Biochemical Investigations:  
Serum and Urine was used for the estimation of biochemical parameters. Samples 
of control and experimental rats were analyzed for Protein, Bilirubin, Urea, Creatinine, 
Triglyceride, Cholesterol and Glucose levels was carried using standard methods. 
Activities of glutamate Oxaloacetate transaminase/ Aspartate aminotransferase 
(GOT/AST), Glutamate pyruvate transaminase/ Alanine amino transferase (GPT/ALT) 
and Alkaline phosphatase were estimated as per the colorimetric procedure.  
Necropsy:  
All the animals were sacrificed on day 29. Necropsy of all animals were carried 
out and the weights of the organs including Liver, Kidneys, Brain, Heart, and Lungs were 
recorded. The relative organ weight of each animal was then calculated as follows; 
     Absolute organ weight (g) 
Relative organ weight = ____________________________________________ ×100 
    Body weight of rats on sacrifice day (g) 
Histopathology:  
Histopathological investigation of the vital organs were done. The organ pieces 
(3-5µm thick) were preserved and were fixed in 10% formalin for 24 h and washed in 
running water for 24 h. Samples were dehydrated in an auto technicon and then cleared in 
benzene to remove absolute alcohol.  Embedding was done by passing the cleared 
samples through three cups containing melted paraffin at 50°C and then in a cubical block 
of paraffin made by the “L” moulds. It was followed by microtome and the slides were 
stained with Haematoxylin-eosin.   
The organs included Brain, Heart, Kidneys, Liver and Lungs of the animals were 
preserved they were subjected to histopathological examination. 
Statistical analysis:  
Findings such as clinical signs of intoxication, body weight changes, food 
consumption, and hematology and blood chemistry were subjected to One-way Anova.   
 
  
 
 
Repeated dose 90 days oral 
toxicity 
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               REPEATED DOSE 90  DAYS ORAL TOXICITY STUDY OF 
                  THIRIKADUGU DRAVAGAM ON WISTAR ALBINO RATS 
 
Test Substance : THIRIKADUGU DRAVAGAM 
Animal Source :  King institute of technology, Guindy.   
Animals :  Wister Albino Rats (Male-12 and Female-12) 
Age : 6-8 weeks 
Body Weight  : 150-200gm. 
Acclimatization : Seven days prior to dosing. 
Veterinary examination :  Prior and at the end of the acclimatization period. 
Identification of animals  : By cage number, animal number   and    individual    
   marking by using picric acid  
Diet : Pellet feed supplied by Sai meera foods Pvt Ltd,  
    Bangalore 
Water : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages  
   provided with bedding of husk. 
Housing temperature :  between 22ºC±3ºC.  
Relative humidity :  between 30% and 70%, 
Air changes  : 10 to 15 per hour  
Dark and light cycle  : 12:12 hours. 
Duration of the study :  90 Days. 
IAEC : NIS/IAEC-1/2016/04 
41 
 
Methodology: 
Randomization, Numbering and Grouping of Animals: 
24 Wistar Albino Rats (12M + 12F) were selected and divided into 4 groups. Each 
group consist of  6 animals (Male 3- and Female-3). First group treated as a control and 
other three group were treated with test drug (low, mid, high) for 90 days. Animals were 
allowed acclimatization period of 7 days to laboratory conditions prior to the initiation of 
treatment. Each animal was marked with picric acid. The females were nulliparous and 
non-pregnant. 
Justification for Dose Selection: 
         As per OECD guideline three dose levels were selected for the study. They were 
low dose (X), mid dose (5X), high dose (10X). X was calculated by multiplying the 
therapeutic dose (10 ml) and the body surface area of the rat (0.018).i.e X dose was 
1ml/kg , 5X dose was 5ml,10X dose was 10ml/kg. 
Preparation and Administration of Dose: 
Thirikadugu  dravagam  was suspended with distilled water. It was administered 
to animals at the dose levels of X, 5X, 10X. The test substance suspensions were freshly 
prepared every two days once for 90 days. The control animals were administered vehicle 
only. The drug was administered orally by using oral gavage once daily for 90 
consecutive days. 
Observations: 
Experimental animals were kept under observation throughout the course of study 
for the following: 
Body Weight: 
 Weight of each rat was recorded on day 0, at 15 days intervals throughout the 
course of study. 
Food and water Consumption:  
 Food and water consumed per animal was calculated for control and the treated 
dose groups.  
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Clinical signs: 
All animals were observed daily for clinical signs. The time of onset, intensity and 
duration of these symptoms, if any, were recorded. 
 
Mortality:  
All animals were observed twice daily for mortality during entire course of study. 
Necropsy: 
All the animals were sacrificed by excessive anesthesia on day 91. Necropsy of all 
animals was carried out. 
Laboratory Investigations: 
Following laboratory investigations were carried out on day 91 in animals fasted 
over-night. Blood samples were collected from orbital sinus using sodium heparin 
(200IU/ml) for Bio chemistry and potassium EDTA (1.5 mg/ml) for Hematology as 
anticoagulant. Blood samples were centrifuged at 3000 r.p.m. for 10 minutes. 
Haematological Investigations: 
   Haematological parameters were determined using Haematology analyzer.  
Biochemical Investigations:  
        Biochemical parameters were determined using auto-analyzer. 
Histopathology:  
Control and highest dose group animals were initially subjected to 
histopathological investigations. If any abnormality found in the highest dose group than 
the low, then the mid dose group was examined. Organs were collected from all animals 
and preserved in 10% buffered neutral formalin for 24 h and washed in running water for 
24 h.  The organ sliced 5 or 6µm sections and were dehydrated in an auto technicon and 
then cleared in benzene to remove absolute alcohol. Embedding was done by passing the 
cleared samples through three cups containing molten paraffin at 50°C and then in a 
cubical block of paraffin made by the “L” moulds. It was followed by microtome and the 
slides were stained with Haematoxylin-eosin. 
 
Statistical analysis:  
              Findings such as clinical signs of intoxication, body weight changes, food 
consumption and hematology and blood chemistry were subjected to One-way ANOVA 
followed by dunnet test using a computer software programme -INSTAT-V3 version  
  
 
 
Pharmacological 
Studies 
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7.1   PHARMACOLOGICAL STUDY OF THIRIKADUGU 
DRAVAGAM 
BRONCHO-DILATOR ACTIVITY 
Aim:  
          To evaluate Bronchodilator activity using Guinea pig by Isolated tracheal chain 
preparation method. 
Procedure: 
All  the  animals  were  fed  with  standard  diet  and  water  ad-libitum and 
maintained under standard laboratory conditions. Guinea pigs of either sex, weighing 
250-300 g were sacrificed by cervical dislocation and carotid bleeding. The trachea was 
dissected out and transferred to a dish containing kreb’s solution (composition (g/l): NaCl 
(6.8), KCl (0.35), CaCl2 (0.28), MgSo47H2O (0.25), NaHCO3 (2.1), KH2PO4 (0.16) and 
glucose (2.0)) and cut transversely between the segments  of  the  cartilage  so  as  to  give  
a  number  of  rings  of  the trachea.  About  5-6  rings  these  were  tied  to  form  a  chain  
of  approximately  4-5  cm  length,  which  was  in  kreb’s solution, contained  in  an  
organ  bath  maintained  at  37°C  and  continuously aerated with carbogen (95% O2+5% 
CO2). One end of the tracheal chain was attached to a tissue holder at the base of organ 
bath and the other end to a frontal lever; the responses were recorded on a slow moving 
kymograph.  The  suspended  tracheal  was  allowed  to  stabilize  for  at  least  30 
minutes.  During  stabilization,  the  bath  was  supplied  with  fresh  kreb’s  solution  ones  
per  every  15  minutes.  Then cumulative concentration response to histamine in the 
absence and presence of  Thirikadugu dravagam were recorded with  a  slow moving 
(0.25 mm/sec) kymograph. 
 Anti-histaminic activity  
Aim 
To evaluate Anti-histaminic activity of Thirikadugu dravagam using Guinea pig in vivo. 
*** KK. College of Pharamacy 
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Procedure:  
 Overnight  fasted  guinea  pigs  were  divided  into 4  groups  each containing 6  animal.   
y Group 1 was treated as control,   
y Group 2 received standard drug chlorpheniramine maleate (2 mg/kg).   
y Groups 3, 4  Thirikadugu dravagam (1 and 2ml/kg).  
All the doses were given orally once a day for 7 days. Prior to drug treatment each 
animal was placed in the histamine chamber and exposed to 0.2 % histamine aerosol. The 
pre convulsive dysponea (PCD) was determined from the time of exposure to onset of 
convulsions. As soon as the PCD were noted, the animal were removed from the chamber 
and placed in fresh air. Group 2 received Chlorpheniramine maleate. Group 3 and 4 
received thirikadugu dravagam at the dose of 1ml and 2ml/kg bw respectively. These  
animals  were  again  subjected  to  histamine  aerosol  after  1hr of  drug  administration  
and  PCD  was determined.  
ANTI-INFLAMMATORY 
Aim: 
   To Evaluate the anti-inflammatory activity of Thirikadugu dravagam on wistar 
albino rats by carageenan induced paw edema. 
Procedure: 
 (Thirikadugu Dravagam (1 and 2ml/kg) or indomethacin (10 mg/kg) was 
administered orally to four groups each group containing 6 animals. Acute in ammation 
was induced half an hour after above treatment by sub-planter injection of 0.1 ml freshly 
prepared 1% suspension of carrageenan in right hind paw in rats (Winter et al., 1962) The 
paw volume was measured initially and then at 1, 2, 3and 4 h after the carrageenan 
injection by using plethysmographic method of Harris and Spencer 1962). 
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RESULTS 
In My research, studies like  Organoleptic characters, physical characters, chemical 
analysis, phytochemical analysis, Elemental analysis, Gas chromatography, Toxicity and 
pharmacological studies have been carried to know the potency and efficacy of the drug 
Thirikadugu dravagam.
Botanical aspect explains the active principle and medicinal uses of 
the plants.
Gunapadam review brings the effectiveness of the drug in treating 
Bronchial ashtma..
The pharmacological review explains about the methodology of Bronchodilator ,
Anti-histaminic activity and the drugs used.
Analytical study of the drug is more essential to derive the efficacy, potency of the 
drug by analysing it by various studies. Following are the results of physicochemical ,
Phytochemical analysis, estimation of basic and acidic radicals, Elemental analysis, GS-
MC have been done and tabulated.
Toxicological results of the drug and pharmacological activity of the drug were
derived. Its result has been tabulated and interpretation was made below. Thus it is to give 
a complete justification to bring the effectiveness of the trial drug Thirikadugu dravagam.
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5.1 ORGANOLEPTIC CHARACTERS
Table : 1  Organoleptic characters of Thirikadugu dravagam
S.NO Parameters Results
1 Colour pale yellow
2 Odour Aromatic odour
3 Taste pungent
4 State of matter liquid
5.2 PHYSICAL CHARACTERIZATION
Table 2 Physical characterization of  Thirikadugu dravagam
S.NO Parameters Results
1 pH 4.65
2 Specific Gravity 0.9992
3 Volatile  Matter Negligible
5.3 CHEMICAL ANALYSIS
Table: 3 Result of Acid radical study:
S.NO Parameter Result
1 Test for Sulphate Negative
2 Test for Chloride Positive
3 Test For Phosphate Negative
4 Test For Carbonate Negative
5 Test For Nitrate Negative
6 Test for Sulphide Negative
7 Test For Fluoride &oxalate Negative
8 Test For Nitrite Negative
9 Test For Borax Negative
Interpretation
The acidic radicals test shows the presence of Chloride
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Table 4 5.3 b :  Results of basic radicals studies.
S.NO Parameter Result
1 Test for Lead Negative
2 Test for Copper Negative
3 Test For Aluminium Negative
4 Test For Iron Negative
5 Test For Zinc Negative
6 Test for Calcium Positive
7 Test For Magnesium Negative
8 Test For Ammonium Negative
9 Test For Potassium Negative
10 Test For Sodium Negative
11 Test For Mercury Negative
12 Test For Arsenic Negative
 
Interpretation
The basic radical test shows the presence of, calcium and absence of heavy metals 
such as lead, arsenic and mercury.
5.4 TLC AND HPTLC  -Table 5
s.no 254 nm 366nm
Dipped in vanillin-
Sulphuric acid
Colour Rf Colour Rf Colour Rf
1
Green 0.66 Blue 0.76 Blue 0.29
2 Green
0.70 Blue 0.94 Grey 0.84
3 Green 0.83 Pink 0.95
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5.5 ELEMENTAL ANALYSIS
INDUCTIVELY COUPLED PLASMA OPTICAL EMISSION SPECTROMETRY
( ICP-OES)
Table : 6
S.NO Elements wavelength in nm Thirikadugu dravagam
1 Arsenic As 188.979 BDL
2 calcium Ca  315.807 15.860 mg/L
3 cadmium Cd  228.802 BDL
4 copper Cu  327.393 BDL
5 Mercury Hg 253.652 BDL
6 Potassium K  766.491 03.821mg/L
7 Sodium Na  589.592 02.520mg/L
8 Nickle Ni   231.604 BDL
9 Lead Pb 220.353 BDL
10 Phosphorous P 213.617 26.358mg/L
BDL  - Below Detection limit
The results shows quantitative analysis of the elements present in Thirikadugu 
dravagam. The heavy metals were  found to be within normal limits. The presence of 
other elements shows the therapeutic value of Thirikadugu dravagam. Hence the drug is 
consider as safe dug.
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5.6 GAS CHROMOTOGRAPHY( GS-MC)
Gas chromtograph of  Thirikadugu dravagam
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GAS CHROMOTOGRAPHY RESULTS OF THIRIKADUGU DRAVAGAM
Table-7
S.No RT Name of the compound
Molecular 
formula
Molecular 
weight(gm/mol)
1. 7.5 9-Methyl-Z-10-Pentadecan -1-ol C10 H20 O 156.27
2. 8.87 Tetradecane,2,6,10-trimethyl C17 H3 6 240.4677
3. 10.17
2-(2-Azepan-1-yl-2-oxoethyl)-1-
hydroxy-1-phenyl-octahydro-
pyridol(1,2-a)azepin-4-one
C24 H34 N2 O3 398.53836
4. 11.4 1-Hexadecanol,2-Methyl C17 H3 60 256.4671
5. 12.58
N(2(1-Piperazyl)ethyl)-N-(2-
thiophosphatoethyl)1,3-
propanamine
C11 H27 N4 O3
PS
326.395842
6. 15.07
Pentadecanoic acid,13-
Methyl,methyl ester
CH3 (CH2)13 
COOH
242.40
7. 15.77 Ethanol,2-(octadecayloxy) C20 H42 O2 314.55
8. 16.08
8-Octadecenoic acid,methyl 
ester,(E)
C19 H36 O2 296.48794
Through GC-MS Analysis, can find the name, molecular weight and structure of 
the compoments of the test drug Thirikadugu dravagam. Images shows  the characteristic 
Gas chromotograph of Thirikadugu dravagam.
In this sample there are 8 compounds were identified, they are the following
9-Methyl-Z-10-Pentadecan-1-ol
Tetradecane,2,610-trimethyl-
2-(2 Azepan-1-yl-2-oxoethyl)-1-hydroxy-1-phenyl-octahydro-phyrido(1,2-
a)azepin-4-one
1-Hexadecanil,2-Methyl
N-(2-(1-piperazyl)-N-(2-thiophosphatoethyl)-1,3-propanamine
Pentadecanoic acid, 13-methyl-methyl ester
Ethanol,2-(octadecyloxy)
8-octadecenoic acid, methyl ester,(E)
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TOXICITY STUDY OF THIRIKADUGU DRAVAGAM
ON WISTAR ALBINO RATS
6.1 ACUTE ORAL TOXICITY STUDY
Table :8 Dose finding experiment and its behavioural Signs of Acute oral toxicity
No Dose 
ml/kg
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
1 1 + - - - - + - - - - - - - - - - - - - -
2 5 + - - - - + - - - - - - - - - - - - - -
3 10 + - - - - + - - - - - - - - - - - - - -
1.Alertness 2.Aggressiveness 3.Pilo erection 4.Grooming 5.Gripping 6.Touch 
Response 7.Decreased Motor activity 8.Tremors 9.Convulsions 10.Muscle Spasm 
11.catatonia 12.Muscle relaxant 13.Hypnosis 14.Analgesia 15.Lacrimation 
16.Exophthalmos 17.Diarrhoea 18. Writhing 19.Respiration 20.Mortality
 ( + )  Indicates presence
( -)   Indicates absence
Interpretation
The acute toxicity result shows no mortality rate up to dose level of 10ml/kg. The 
normal behavioural changes were observed in first four hours and no mortality was 
reported after 14 days observation. Hence the test drug Thirikadugu dravagam is safe up 
to the dose of  level of 10ml/Kg in oral administration. 
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REPEATE 28  DAYS ORAL TOXICITY STUDY OFTHIRIKADUGU 
DRAVAGAM ON WISTAR ALBINO RATS
Table : 9 Body weight of wistar albino rat groups when exposed to thirikadugu 
dravagam
Treatment
0th 
day
5th 
day
10th  
day
15st 
day
20th 
day
25th 
day
28th 
day
Control
155.25
±2.54
159.47±
6.25
161.55
±4.48
164.53±
2.71
166.77
±6.11
169.21
±4.22
171.66
±3.20
Mid dose
171.15
±6.58
173.83±
6.55
175.33
± 4.31
176.53±
4.25
178.32
±3.28
180.16
±4.37
182.83
±5.37
High dose
158.83
±9.54
159.66±
6.09
160.50
±3.58
163.01±
7.26
165.33
±7.54
168.53
±8.31
170.16
±5.61
 
Data are expressed as mean ± SEM (n = 10 for each group), *P < 0.05, **P<0.01
were considered significant using One way ANOVA followed by Dunnett’s test
Table: 10 Relative Organ Weight of wistar albino rat groups when exposed to 
thirikadugu dravagam
Dose
Relative Organ Weight of rats
Liver Kidney Brain Lungs Heart Spleen
Control 2.8±0.1 0.66±0.02 0.38±0.22 0.29±0.01 0.29±0.01 0.15±0.01
Mid dose 2.89±0.1 0.65±0.02 0.42±0.01 0.30±0.02 0.31±0.01 0.17±0.01
High dose 3.01±0.1 0.66±0.03 0.42±0.01 0.31±0.01 0.31±0.01 0.16±0.01
Data are expressed as mean ± SEM (n = 10 for each group), *P < 0.05, **P<0.01
were considered significant using One way ANOVA followed by Dunnett’s test
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Table : 11 Sub acute toxicity study - Food intake (gms/day) of Wistar albino rats group 
exposed Thirikadugu dravagam
Treatment 0th day 7th day 14th day 21th day 28th day
Control 37.83±1.8 36.50±1.67 38.83±1.31 39.66±1.46 40.66±1.50
Mid dose 40.16±0.38 42.33±0.60 42.83±0.61 43.16±1.32 44.13±1.37
High dose 40.63±0.58 42.66±1.09 43.01±1.56 43.53±1.31 44.16±1.67
 
N.S- Not Significant, **(p < 0.01), *(p <0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test)
Table : 12 Sub acute toxicity study - Water intake (ml/day) of Wistar albino rats group 
exposed to THIRIKADUGU DRAVAGAM
Treatment 0th day 7th day 14th day 21th day 28th day
Control 30.0±0.48 31.16±0.22 31.13±0.33 32.2±0.16 35.46±0.34
Mid dose 31.73±0.89 32.52±1.22 32.41±1.11 34.45±1.05 35.64±1.42
High dose 32.66±1.15 35.01±1.64 33.33±1.77 34.16±1.43 36.5±1.52
Data are expressed as mean ± SEM (n = 10 for each group), *P < 0.05, **P<0.01 were 
considered significant using One way ANOVA followed by Dunnett’s test
 
 
 
 
 
62
Table: 13 :Hematological Parameter of Thirikadugu dravagam
Haematological parameter Control
Thirikadugu dravagam
Mid dose High dose
Total R.B.C. count (×106 mm 3). 9.09±0.15 9.11±0.85 9.61±0.16
TotalW.B.C. Count (×103 mm 3). 12.67±0.22 12.62±0.526 12.72±0.072
Haemoglobin (Hb) (g/dl) 14.61±0.36 14.68±0.475 14.81±0.781
Hematocrit (%). 44.21±1.01 42.7± 0.852 42.75±1.072
Platelets (×103 mm 3). 830.91±24.01 832.21±21.55 833.58±15.25
Lymphocytes(%). 72.7±1.32 75.28±2.63 77.8±5.58
Neutrophils (%). 20.6±0.65 19.6±1.357 19.9±0.69
Data are expressed as mean ± SEM (n = 6 for each group), *P < 0.05, **P<0.01 were 
considered significant using One way ANOVA followed by Dunnett’s test
Chart I : Sub acute toxicity  - The mean value of  Total RBC, WBC  and HB of control 
and treated groups Of wistar  albino rats exposed to Thirikadugu dravagam
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Chart  2 - Sub acute toxicity  - The mean value of  Total Neutrophil, leucocyte  and 
hematocrit of control and treated groups of wistar  albino rats exposed to 
Thirikadugu dravagam.
 
Chart -3 Sub acute toxicity  - The mean value of  Platelets of control and treated groups 
of wistar  albino rats exposed to Thirikadugu dravagam.
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Table: 14 Biochemical Parameters of Thirikadugu dravagam 
Biochemical parameter Control
Trail drug
Mid dose High dose
Creatinine (mg/dl) 0.52±0.079 0.54±0.07 0.57±0.29
Urea (mg/dl) 14.30 ± 0.47 14.33±0.49 14.74±1.078
Blood Glucose(R) 109±0.41 110±0.371 118±0.261
Triglycerides (mg/dl) 50.20±1.13 52.23±1.08 49.17±1.86 
Total Cholesterol (mg/dl) 46.60±1.21 45.460±1.08 45.836±1.05 
Total protein (mg/dl) 4.40±0.267 4.12±0.371 4.220±0.41 
Albumin (g/dl) 3.20±0.41 3.30±0.351 3.29±0.261 
AST (IU/L) 121.41±2.68 119.8±4.67 120.76±4.086 
ALT (IU/L) 68.40±1.57 69.012±.2.32 69.99±3.521 
ALP (IU/L) 112.6±4.67 115.01±1.021 116.41±2.108 
T. Bilirubin (mg/dl) 0.91±0.32 0.83±1.012 0.88±01.82 
Values are mean ±S.E.M. (n=10) ***p<0.001, ** p<0.01, * p<0.05 compared with the 
control animals. 
Chart -4  Sub acute toxicity  - The mean value of  Urea, creatinine  of control and 
treated groups of wistar  albino rats exposed to Thirikadugu dravagam
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Chart- 5  Sub acute toxicity  - The mean value of T.Cholestrol, Trigylcerides,B lood 
Glucose of control and treated groups of wistar  albino rats exposed to 
Thirikadugu dravagam
 
Chart-6  Sub acute toxicity  - The mean value of T.Bilirubin, AST,ALT  of control and 
treated groups of wistar  albino rats exposed to Thirikadugu dravagam
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HISTOPATHOLOGY OF THIRIKADUGU DRAVAGAM – REPEATED 
DOSE 28 DAYS ORAL TOXICITY STUDY
BRAIN LIVER
1Control Control
Mid dose                                       Mid dose
High dose High dose
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KIDNEY                                                       HEART
Control                                         Control
Mid dose Mid dose
High dose High dose
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LUNGS
       Control                                                                            Mid dose
High dose
RESULT
The above slide shows the histopathology studies of sub-acute toxicity studies. There is 
no toxicological abnormality seen in vital organ after administration of the test drug 
Thirikadugu dravagam. Thus the safety of the drug is revealed so that it can be administered 
for longtime without any side effects
All animals from control and all the treated dose groups survived throughout the dosing 
period of 28 days for sub acute toxicity study. There was no significant change in the body 
weight for the control and treatment group throughout the dosing period of 28 days.
The results of haematological investigations conducted on day 29th day revealed no 
significant changes in the haematological values when compared with those of respective 
controls. This gave clear justification that bone marrow and spleen were not influenced by 
Thirikadugu Dravagam.
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Results of Biochemical investigations conducted on days 29 and recorded in revealed 
the no significant changes in the values of different parameters studied when compared with 
those of respective controls; Urea, SGOT,SGPT, Bilirubin were within the limits. 
The other cardio vascular risk markers were also within normal ensured that 
Thirikadugu Dravagamdid not influence the Cardio vascular system.
The vital organs such as liver, heart, kidneys, lungs and brain were removed from the 
test groups at the end of the study and carefully observed macroscopically to find any 
observable gross lesions compared with the control group and did not reveal any abnormal 
macroscopic changes. Cross pathological investigation was carried out and histopathology of 
vital organ reveled normal histological appearance when compared with the control.
Organ weights of treated animals with respective control animals on day 29 was 
found to be comparable with respective control group. Gross pathological examination of 
animals  did not reveal any abnormalities. Histopathology examination did not reveal any 
abnormal macroscopic changes.
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Table ; 15  6.3  Sub-chronic toxicity study - Body weight of  wistar albino rats when 
exposed to Thirikadugu dravagam
NS  Non Significant, **(p > 0.01),*(p >0.05), n =6 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test
Table 16 : Sub-Chronic Toxicity Study – Hematological parameters of
Thirikadugu Dravagam
Parameters control
TD 
(lowdose)
TD (Mid 
dose)
TD (High dose)
RBC cells/cu.mm 7.5± 0.38 7.23±0.40 7.26±0.22 7.21±0.37
WBC cells/cu.mm 9586±417 11016±483 11016±549 11350±500
Platelet cells/ul 3.4±0.27 3.68±0.11 3.41±0.34 3.26±0.22
PCV % 38.85±2.70 39.5±2.33 39.5±2.33 40.1±1.6
HB (g/dl) 12.95±0.90 13.16± 0.78 13.2± 1.02 13.2±0.35
MCV 93.5±6.89 95±2 91±7.37 93.66± 3.22
MCH 32.83±2.31 32.66±3.72 34.5±5.85 33.5±1.37
MCHC 34.83±2.48 32.16±2.92 34.16±2.48 33.83±2.71
DAYS
GROUPS
Control Low dose Mid dose High dose
1 163.6±33.683 150.1 ± 21.105 158.6± 13.57 168.5± 28.75
15 172.8 ± 28.870 161.5 ± 21.706 175.7 ± 29.01 182.8 ± 32.48
30 185.8 ± 28.310 186.7 ± 14.88 186.8 ± 32.11 190 ± 28.94
45 204.5± 27.73 205.5± 29.76 206.7± 19.75 207± 22.75
60 227.6±33.683 233.6±23.683 237.6±33.683 224.6±23.783 
75 242.8 ± 26.85 247.8 ± 28.870 242.8 ± 28.870 243.8 ±26.870
90 265± 27.320 267± 27.320 268± 27.320 266± 36.320*
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Table 17   Biochemical parameter Sub-Chronic Toxicity Study 
of Thirikadugu Dravagam
Parameters control TD low dose TD Mid dose TD High dose
Glucose mg/dl 94.66±14.34 114.16±6.27 120.5±6.59 107±14.05
Urea mg/dl 29.5±8.89 26.66±3.88 30.33±12.90 34.83±4.99
Creatinine 
mg/dl
0.58±0.13 0.51±0.14 0.58±0.20 0.51±0.11
T.Bilirubin 
mg/dl
0.58±0.07 0.65±0.10 0.81±0.07 0.71±0.17
SGOT  (U/dl ) 22.33±7.31 24±8.22 22±5.44 26.16±5.60
SGPT ( U/dl) 25.66±4.96 24±3.84 28±5.65 27.83±5.98
ALP  ( U/dl ) 63.±8.07 77.33±17 75.16±11 60.5±9.93
T.Cholestrol 
mg/dl
119.16±7.11 114±5.17 105.83±11.12 112.6±4.80
HDL mg/dl 37±4.14 41.16±2.78 42.33±3.38 39.16±3.48
LDL mg/dl 55.66±6.12 44.66±5.50 36.5±12.72 47.66±1.36
VLDL mg/dl 28.56±5.76 28.76±4.31 28.63±3.44 24.5±0.95
Data are expressed as mean ± SEM (n = 6 for each group), *P < 0.05, **P<0.01 were
considered significant using One way ANOVA followed by Dunnett’s test
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Chart 8-Sub Chronic toxicity  study- The mean value of T.RBC, Hb &platelet  of control and 
treated groups of wistar  albino rats exposed to Thirikadugu dravagam
Chart-9 Sub Chronic toxicity  study- The mean value of MCV, MCH,MCHC&PCV of 
control and treated groups of wistar  albino rats exposed to Thirikadugu dravagam
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Chart 10 Sub Chronic toxicity  study- The mean value of WBC of control and treated 
groups of wistar  albino rats exposed to Thirikadugu dravagam
Chart 11- Sub Chronic toxicity  study- The mean value of urea and creatinine of control 
and treated groups of wistar  albino rats exposed to Thirikadugu dravagam
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Chart 12- Sub Chronic toxicity  study- The mean value of lipid profile of control and 
treated groups of wistar  albino rats exposed to Thirikadugu dravagam
Chart 13- Sub Chronic toxicity  study- The mean value of  liver function test of control 
and treated groups of wistar  albino rats exposed to Thirikadugu dravagam
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Chart 14-Sub Chronic toxicity  study- The mean value of  Blood glucose of control and 
treated groups of wistar  albino rats exposed to Thirikadugu dravagam
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          6.3 -Histopathology Reports for Sub chronic toxicity studies
Histopathology reports of  Sub-chronic toxity study of Thirikadugu dravagam when exposed to 
Control group of wistar albino rat.
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Histopathology reports of  Sub-chronic toxity study of Thirikadugu 
dravagam when exposed to High dose group of wistar albino rat.
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Histopathology report
Kidney
Junction between cortex and medulla appears distant
Derangement in Interstitial connective tissue was observed in sample belongs to 
4HM 
No signs of cellular necrosis 
Proximal and distal convoluted tubule appears normal
Heart
Myocardial fiber mass appears denser with no signs of degeneration or fibrosis.
Appearance of cardiomyocyte was normal with dark nuclear region. The nuclei of 
muscle fibers appear oval arrangement.
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Liver
Appearance of portal vein was normal 
Appearance of hepatic cord was normal and radial in nature, no signs of cellular 
degeneration
Lung
Lung parenchyma appears normal with regular arrangement of alveoli and alveolar 
sac with no signs of lymphocyte infiltration and pulmonary fibrosis
Perivascular region appears normal, Alveolar septa and wall appeared widen and 
normal
No signs of lymphocyte cuffing
No signs of airway secretion and bronchial secretion
Bronchial blood vessels and connective tissue appears normal with no sings of 
pulmonary edema
Stomach
Light microscopic observation of both the sample reveals normal histology of rat 
gastric wall composed of mucosa, muscularismucosa, submucosa, muscularispropiria 
and adventitia. 
No signs of ulceration were observed
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Interpretation of Sub-chronic toxicity of Thirikadugu dravagam
Sub-chronic oral toxicity repeated dose of T hirikadugu dravagam on rats were 
conducted. All animals from the treated dose survived throughout the dosing period of 90 
days. Various parameters were studied and the interpretation of the study result is discussed 
below.
Body weight
The result of the body weight of rats exposed to control and the Thirikadugu 
dravagam of different dose groups exhibited overall weight gain throughout the dosing 
period of 90 days. The quantity of food taken by the animals from different dose groups and 
the control is comparably normal.
Haematological investigation interpretation:
The haematological investigation results of the rats conducted on 91st   day after the 
repeated dose of the drug revealed the values of different parameters. The increase and 
decrease in the values obtained were all within the normal biological and laboratory limits.
Biochemical investigation interpretation:
The biochemical investigations were conducted on 90th day and the result is 
produced. The results revealed there are no significant changes in the values of different 
parameters with that of the control. values  were within the normal biological and laboratory 
limits.
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7.1 PHARMACOLOGICAL RESULTS OF THIRIKADUGU DRAVAGAM
Bronchodilator activity using isolated guinea pig tracheal chain preparation
Result
The contractile of tracheal chain in vitro has often been utilized for the study of 
contractile response of agonists as well as antagonist.spasmogen such as histamine produces 
dose dependent contraction of guinea pig tracheal chain preparation. In the present study, the 
trial drug Thirikadugu dravagam significantly inhibited the histamine- induced contractions 
of isolated guinea pig tracheal chain preparation, indicating Bronchodilator activity
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7.2 Anti-histaminic activity Of Thirikadugu dravagam using Guinea pig
Table :18
Serial No Group Onset  of Convulsion  in sec.
1 Control 9x.67± 2.028
2
Standard (Chlopheniramine 
maleate)
596.7± 46.31***
3 Thirikadugu Dravagam (1ml/kg) 131.7± 6.00 *
4 Thirikadugu Dravagam (2ml/kg) 310.0± 20.82 **
Values are mean ±S.E.M. (n=6) ***p<0.001, ** p<0.01, * p<0.05 compared with the 
control animals.
Result
The result of present study suggested that guinea pig exposed to histamine aerosol 
showed Signs of progressive Dysponea leading to convulsions. The two doses of Thirikadugu 
dravagam prolonged the latent period of convulsion as compared to control following the 
exposure to histamine aerosol. Thus our findings suggest that Thirikadugu dravagam possess 
significant antihistaminic activity. 
0
100
200
300
400
500
600
Control CPM TD 1ml/kg TD 2ml/kg
91.67
596.7
131.7
310
Onset of Convulsions
84
7.3 Anti-inflammatory activity:
Results:
Treatment
Percentage inflammation after carageenan injection at hr
1 2 3 4
Control 51.08±3.12 91.25±7.78 140.15±8.27 150.16±2.87
T.Dravagam
1ml/kg
36.50±5.58
**
78.50±3.54 *
100.18±2.29 
**
107.45±5.68 
**
T.Dravagam  
2ml/kg
26.62±2.26
***
61.12±3.90
***
74.16±6.16
***
70.34±2.12
***
Indomethacin 
10mg/kg
21.45±7.87
***
37.43±3.23
***
40.79±2.94
***
35.50±3.14
***
Values are mean ±S.E.M. (n=6) ***p<0.001, ** p<0.01, * p<0.05 compared with the 
control animals.
Thirikadugu dravagam exhibited significant anti-inflammatory activity when compare 
to the control group.
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9. DISCUSSION
The drug Thirikadugu dravagam was selected from the siddha literature “yaakobu 
vaithiya chinthamani” 700 to evaluate the safety and Pharmacological profile in animal 
models.
The ingredients of the test drug was identified and authenticated by Botanist, The 
standard operative procedure were followed.
Review of various information Relevant to the study  Both Modern and Siddha Aspect 
supported the study.
According to AYUSH protocol Physical characterization, like PH, Specific Gravity 
were  evaluated. PH  of Thirikadugu dravagam is 4..65, Eventhough it is acidic, Siddhars 
indicated this for internal use with equal amount of water, to Neutralise the acid.
Specific Gravity is commonly used in pharmaceutical laboratory to determine the 
concentration of the solution. Specific gravity of Thirikadugu dravagam is 0.9992.
Elemental analysis is also essential to ensure the Safety and efficacy of drug. Test drug 
shows heavy metals below the detected limit.
GC-MS: Have been used for identification of large number of components present in   
natural and  biological systems. Hence the drug is consider as safe drug.
chemical analysis: chemical analysis of the drug Thirikadugu dravagam reveals that 
the presence Chloride. Calcium, alkaoloids.
All these analytical studies shows, The drug is safe and shows Sufficient Molecules of  
therapeutic benefits for the safety and efficacy of  the Drug Thirikadugu Dravagam.
Toxicological studies:
Before going to clinical study, It is essential to evaluate the toxicity stiudes. TheSE
studies are important to Globalise the siddha system of medicine.  Based on these  Acute, 
Sub-acute, and Sub-chronic studies were carried out using wistar albino rats.
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This study reveals that, no significant toxic effect of the  drug Thirikadugu dravagam 
upto the higher dose level of 10ml/kg in acute oral toxicity, sub- acute and sub chronic 
toxicity studies. Therefore the drug Thirikadugu dravagam is safe on animal experimentation, 
and there is no toxicity of administration. Hence it can be classified under the category of 
drug with non-toxic.
Pharmacological studies:
Pharmacological study was carried out in animal models Tthe experimental data 
showed that Thirikadugu dravagam has bronchodilator, Anti-histaminic Anti-inflammatory 
activity and the results are as follows,
Bronchodilator activity:
The contractile of tracheal chain in vitro has often been utilized for the study of 
contractile response of agonists as well as antagonist.spasmogen such as histamine produces 
dose dependent contraction of guinea pig tracheal chain preparation. In the present study, the 
trial drug Thirikadugu dravagam significantly inhibited the histamine- induced contractions 
of isolated guinea pig tracheal chain preparation, indicating Bronchodilator activity
Anti-histaminic activity:
The result of present study suggested that guinea pig exposed to histamine aerosol 
showed singns of progressive Dysponea leading to convulsions. The two doses of 
Thirikadugu dravagam prolonged the latent period of convulsion as compared to control 
following the exposure to histamine aerosol. Thus our findings suggest that Thirikadugu 
dravagam possess significant antihistaminic activity. 
Anti- inflammatory activity:
Thirikadugu dravagam exhibited significant anti-inflammatory activity when 
compare to the control
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10 . Summary
The test drug Thirikadugu dravagam was selected from the siddha literature
“Yaaakobu vaithiyachinthamani” for its Bronchodilator, Antihistaminic and Anti-
inflammatory activities.
The test drug was prepared by the given procedure. All the ingredients were identified 
and authenticated by the experts.
Review of literature in various categories was carried out. Siddha aspect, botanical 
aspect disclosed about the drug .
The drug was subjected to analysis such as physicochemical, photochemical, chemical 
analysis,  ICPOES, GC-MS which provided the key ingredients present in the drug 
thus it accounts the efficacy of the drug
Toxicological study was made according to OECD guidelines comprising acute, sub-
acute and sub chronic toxicity study. It screens the safety of the drug.         
Pharmacological study was done. It revealed of Thirikadugu dravagam in animal
model, Bronchodilator, Anti-histaminic activity using Guinea pig and Anti-
inflammatory activities in wistar albino rats.
Results and discussion gives the proper justifications to prove the potency of the drug.
Conclusion gives a compiled form of the study and explains the synergistic effect of
all the key ingredients and activities that supports the study.
Thus the herbal formulation Thirikadugu dravagam is validated for its Safety and 
efficacy for treating Bronchial asthma and it would be a great drug of                        
choice.
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11. CONCLUSION
From the literature evidence, physicochemical analysis, Chemical analysis, 
Toxicological evaluation and Pharmacological studies, the drug Thirikadugu Drvagam has 
Bronchodilator, Anti-histaminic and anti-inflammatory activity. It is concluded that the drug 
Thirikadugu Dravagam can be used in the management of Bronchial asthma and the related 
Respiratory disorders.
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